SAM-315
3182A1-102
Phase 1 small_molecule completed
Quick answer
SAM-315 for Alzheimer Disease is a Phase 1 program (small_molecule) at Wyeth is now a wholly owned subsidiary of Pfizer with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Wyeth is now a wholly owned subsidiary of Pfizer
- Indication
- Alzheimer Disease
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed